Home › GE Healthcare Invests In FISH Technologies For Leukemia And Lymphoma Testing
 

Keywords :   


GE Healthcare Invests In FISH Technologies For Leukemia And Lymphoma Testing

2014-03-05 04:40:25| drugdiscoveryonline Home Page

GE Healthcare recently announced that Clarient Diagnostic Service, Inc., a GE Healthcare company, has made significant upgrades to its fluorescence in situ hybridisation (FISH) technologies to improve virtual analysis of testing results for a variety of blood diseases, including leukemia, lymphoma, myelodysplastic syndrome and myeloma

Tags: technologies testing fish healthcare

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
23.11PlayStationVitaPCH-2000
23.11GB
23.11 Malbon
23.11PING PEARL GATES
23.11WATCH
23.11L
23.11Tetsuya_SP2 DMC
23.116
More »